By Connor Hart
American depositary receipts of Medirom Healthcare Technologies more than doubled after the bell on the disclosure that Tokyo-based venture company M3 is the lead investor of the company's Series A financing round.
ADRs surged 107%, to $6.31, in postmarket trading Friday. Shares ended the regular session 0.3% lower, to $3.07, putting them down 47% since the beginning of the year.
The provider of holistic health services in Japan said M3's pre-money valuation is 9 billion yen ($60 million).
Write to Connor Hart at connor.hart@wsj.com
(END) Dow Jones Newswires
December 06, 2024 17:43 ET (22:43 GMT)
Copyright (c) 2024 Dow Jones & Company, Inc.
免責聲明:投資有風險,本文並非投資建議,以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請,作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考,不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證,投資者應自行研究並在投資前尋求專業建議。